Summary:
A research study testing the safety and effectivenes of the investigational drug boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC subjects.
Qualified Participants Must:
• Be 18 years of age or older
•
Have previous documented Chronic Hepatitis C genotype 1 infection
Qualified Participants May Receive:
Study related care, diagnostic test, and study medication at no cost. Payment for time and travel to the study center may be provided.